Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI (Figure 1).
HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
Result: The major NNRTI DRMs were V179D/E (37.9%, 149/393), V106I/M (25.7%, 101/393), and K103N/Q (25.2%, 99/393) (Table 3).
Table: V106I/M
Discussion: V106I/M, K103N/Q, G190A/S, and Y181C were the major NNRTI-associated mutations, similar to those in other cities in China and other countries, and showed broad-spectrum resistance possibly caused by the wide use of NNRTIs.
Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
Result: Given the low prevalence of non-B subtypes in the study population, associations between specific viral subtypes and the presence of polymorphic mutations were not particularly relevant in the context of the study population, e.g., V106I was present in all F1 subtypes; however, only 6/6661 F1 viruses were observed, while V106IM (generally combined with other NNRTI mutations) was observed in 231/6577 (3.5%) subtype B viruses.
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Result: Of the 41 viraemic specimens genotyped, the major NNRTI resistance-associated mutations detected were: K103N (24.4%), P225H (7.3%), K101E (7.3%), V108I (7.3%), V90I (4.9%), V106M/A (9.8%), H221Y (4.9%), E138G/A (4.9%), and Y181C (4.9%).
Table: V106M/A
Discussion: Interestingly, the finding identified all the four RT gene positions (K103N, Y181C, G190A and V106M) recommended for point of care ge
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Introduction: Several groups have developed point mutation assays (PMAs) that detect key DRMs (K65R and M184V for NRTIs; and K103NS, V106AM, Y181C, and G190A for NNRTIs) which are found in 98.8% of patients failing NNRTI-based 1st line regimens.
Method: Additional DRMs only detected by Sanger to NRTIs (L74I, D67N, K70E and K219R) and NNRTIs (V106M, K101E and
Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.
PMID: 34402512
2021
The Journal of antimicrobial chemotherapy
Abstract: The most common DRMs of these three subtypes were K103N and M184V, while the mutation frequencies of M41L, D67N, K70R, K101E, V106M, Y181C, K219E, H221Y and N348I were obviously different among subtypes.
HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
PMID: 34762770
2021
Journal of the International AIDS Society
Abstract: Overall, 18/168 (11%) had NNRTI mutations including K101E, K103N/S, V106M, V108I, E138A/G, V179D/I/T and
Result: Major NNRTI mutations detected included K101E, K103N, K103S, V106M, V108I, E138A/G, V179D/I/T and H221Y, but the frequency of detection of each of these mutations did not differ by arm (Table 1).
Table: V106M
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.
Introduction: In almost all cases, DOR selected first for V106A/M substitutions.
Introduction: Mutations that emerged secondary to PMID: 32280691
2020
BioMed research international
Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by G190A/E/K/Q/S/V (28.57%, 70/245), V179I/D/E/T (27.76%, 68/245), V106A/I/M (26.12%, 64/245), Y181C/V (18.78%, 46/245), K101E/H/P (14.69%, 36/245), Y188C/H/L (5.71%, 14/245), L100I (4.08%, 10/245), and M230L (4.08%, 10/245).
HIV mutation literature information.
PMID: 
2021
BioMed research international
Browser Board
Co-occurred Entities
Filtrator
ViMRT